Velaglucerase alfa

Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.^[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.^[2] It is manufactured by Shire plc.

Velaglucerase alfa

Clinical data
Trade names	Vpriv
AHFS/Drugs.com	Monograph
License data	US DailyMed: Velaglucerase alfa
Routes of administration	Intravenous
ATC code	A16AB10 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only[1] EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	Plasma: 5–12 minutes (absorbed by macrophages)
Identifiers
CAS Number	884604-91-5 Y
DrugBank	DB06720 Y
ChemSpider	none
UNII	23HYE36B0I
KEGG	D09029
ChEMBL	ChEMBL1201865 N
Chemical and physical data
Formula	C2532H3850N672O711S16
Molar mass	55593.61 g·mol−1
NY (what is this?)  (verify)

The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.^[3]

Velaglucerase alfa was approved for medical use in the United States in February 2010,^[4][5] and in the European Union in August 2010.^[3]

Medical uses

Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.^[3][1]